Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
To compare the antiemetic combination of palonosetron, dexamethasone, and aprepitant (PDA)
with antiemetic combination of palonosetron and dexamethasone (PD) in nasopharyngeal
carcinoma patients receiving docetaxel, cisplatin, and 5-FU based chemotherapy.